Thursday, 24 September 2026European Markets
ExploreSearch
ViaNews EU
Via News Knowledge File

Merck & Co., Inc.

organization80% conf.·synced Sep 24, 2026

Pharmaceutical company based in Rahway, NJ, known as MSD outside US and Canada

60
sourced metrics
660
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week High
156.45USD
Sep 10, 2026reference only
Stock Return Ytd
35.9%
Sep 10, 2026reference only
Price 52 Week Low
77.60USD
Sep 10, 2026reference only
Market Cap
357024407735USD
Sep 10, 2026reference only
Stock Price
144.71USD
Sep 10, 2026reference only
Shares Outstanding
2467171638.0shares
Jul 31, 2026reference only
Cost Of Revenue
4395000000.0USD
Jun 30, 2026reference only
Cash
6849000000.0USD
Jun 30, 2026reference only
Eps
-0.54USD_per_share
Jun 30, 2026reference only
Revenue
16607000000.0USD
Jun 30, 2026reference only
Rd Expense
9741000000.0USD
Jun 30, 2026reference only
Total Assets
129802000000.0USD
Jun 30, 2026reference only
Stockholders Equity
41933000000.0USD
Jun 30, 2026reference only
Net Income
-1335000000.0USD
Jun 30, 2026reference only
Operating Cash Flow
3918000000.0USD
Mar 31, 2026reference only
Capex
991000000.0USD
Mar 31, 2026reference only

Stated objectives

Deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals

source
stated

Build Delaware facility dedicated to Keytruda manufacturing

source
target: 1000000000 USD investment stated

Obtain regulatory approval for enlicitide decanoate as the first oral PCSK9 inhibitor

source
target: FDA approval stated

Enroll approximately 675 patients in KANDLELIT-007 Phase 3 trial

source
target: 675 patients stated

Evaluate progression-free survival as primary endpoint in PD-L1 TPS ≥1% patients in KANDLELIT-007

source
stated

Evaluate secondary endpoints including PFS in all patients, overall survival, objective response rate, duration of response, and safety in KANDLELIT-007

source
stated

Submit regulatory filings worldwide for KEYTRUDA + Padcev combination in muscle-invasive bladder cancer based on KEYNOTE-B15/EV-304 results

source
stated

Initiate second Merck-sponsored pivotal trial of zanzalintinib and belzutifan in RCC

source
stated

Full-year sales forecast

source
target: $64.5 billion to $65 billion by 2025-12-31 00:00:00stated

Full-year EPS forecast

source
target: $8.93 to $8.98 by 2025-12-31 00:00:00stated

Relationship graph · 660 connections

Developed by
267
Competes with
67
Employs
46
acquired by
42
Partnered with
41
Covered by
28
regulates
28
headquartered in
27
headquartered in
Rahway, New Jersey
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Go Mainstream, But Trustworthy Data Access Lags Adoption
A wave of enterprise AI agent activity — fresh funding (Latitude's $35M Series A), a run of CB Insights CEO interviews spotlighting fintech- and healthcare-focused agent startups (Covecta, Penguin AI, Maisa AI), and major platform partnerships (Microsoft-Mistral, Manulife-Microsoft AI governance, Siemens-NVIDIA agentic EDA, Box's agent security controls) — signals agentic AI moving from pilot to production across financial and enterprise workflows. Yet Google Cloud's own research shows adoption is outrunning data readiness (companies average AI access to only 45% of their data, with 'data laggards' capped near 30%), while insider selling at incumbent C3.ai hints at mixed investor conviction even as the broader ecosystem accelerates.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,305 source documents archived
Query this data → isubstrate.com